Literature DB >> 2418021

Metabolism and mode of action of (R)-9-(3,4-dihydroxybutyl)guanine in herpes simplex virus-infected vero cells.

K Stenberg, A Larsson, R Datema.   

Abstract

The metabolism and mode of action of the anti-herpes compound buciclovir [R)-9-(3,4-dihydroxybutyl)-guanine, BCV) has been studied in herpes simplex virus-infected and uninfected Vero cells. In uninfected cells, a low and constant concentration of intracellular BCV was found, while in herpes simplex virus-infected cells, an increasing concentration of BCV phosphates was found due to metabolic trapping. The major phosphorylation product was BCV triphosphate (BCVTP) which was 92% of the total amount of BCV phosphates. BCV phosphates were accumulated to the same extent in cells infected with either a herpes simplex virus type 1 or a herpes simplex virus type 2 strain while thymidine kinase-deficient mutants of herpes simplex virus type 1 were 10 times less efficient in accumulating BCV phosphates. In uninfected Vero cells, the concentration of the phosphorylated forms of BCV was less than 1% of that found in herpes simplex virus-infected cells. The BCVTP formed in herpes simplex virus-infected cells was highly stable, as 80% of the amount of BCVTP was still present even 17 h after removal of extracellular BCV. BCV was a good substrate for herpes simplex virus type 1- and type 2-induced thymidine kinases but not for the cellular cytosol or mitochondrial thymidine kinases. BCV monophosphate could be phosphorylated by cellular guanylate kinase to BCV diphosphate. BCVTP was a selective and competitive inhibitor to deoxyguanosine triphosphate of the purified herpes simplex virus type 1- and type 2-induced DNA polymerases. BCVTP could neither act as an alternative substrate in the herpes simplex virus type 2 or cellular DNA polymerase reactions, nor could [3H]BCV monophosphate be detected in DNA formed by herpes simplex virus type 2 DNA polymerase, or be detected in nucleic acids extracted from herpes simplex virus type 1-infected cells. These data indicate that BCVTP may inhibit the herpes simplex virus-induced DNA polymerase without being incorporated into DNA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418021

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals.

Authors:  M R Boyd; T H Bacon; D Sutton
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

2.  Mutation within the herpes simplex virus DNA polymerase gene conferring resistance to (R)-9-(3,4-dihydroxybutyl)guanine.

Authors:  H C Chiou; K M Kerns; D M Coen
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

3.  Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir.

Authors:  A Larsson; K Stenberg; A C Ericson; U Haglund; W A Yisak; N G Johansson; B Oberg; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

4.  Influence of acyclovir and bucyclovir on nucleotide pools in cells infected with herpes simplex virus type 1.

Authors:  A H Karlsson; J G Harmenberg; B E Wahren
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

5.  Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate.

Authors:  G Abele; B Eriksson; J Harmenberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

6.  Antiviral activities of guanosine analogs in guinea pig embryonic fibroblasts.

Authors:  J Harmenberg; K Stenberg
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

7.  Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells.

Authors:  R A Hodge; R M Perkins
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

Review 8.  Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review.

Authors:  T Kulikowski
Journal:  Pharm World Sci       Date:  1994-04-15

9.  Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells.

Authors:  M T Paff; D R Averett; K L Prus; W H Miller; D J Nelson
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug.

Authors:  D M Lake-Bakaar; G Abele; B Lindborg; K F Soike; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.